Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.
Clin Infect Dis. 2021 Nov 2;73(9):e2853-e2860. doi: 10.1093/cid/ciaa1471.
The objective of this study was to perform a seroprevalence survey on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among Danish healthcare workers to identify high-risk groups.
All healthcare workers and administrative personnel at the 7 hospitals, prehospital services, and specialist practitioner clinics in the Central Denmark Region were invited to be tested by a commercial SARS-CoV-2 total antibody enzyme-linked immunosorbent assay (Wantai Biological Pharmacy Enterprise Co, Ltd, Beijing, China).
A total of 25 950 participants were invited. Of these, 17 971 had samples available for SARS-CoV-2 antibody testing. After adjustment for assay sensitivity and specificity, the overall seroprevalence was 3.4% (95% confidence interval [CI], 2.5%-3.8%). The seroprevalence was higher in the western part of the region than in the eastern part (11.9% vs 1.2%; difference: 10.7 percentage points [95% CI, 9.5-12.2]). In the high-prevalence area, the emergency departments had the highest seroprevalence (29.7%), whereas departments without patients or with limited patient contact had the lowest seroprevalence (2.2%). Among the total 668 seropositive participants, 433 (64.8%) had previously been tested for SARS-CoV-2 RNA, and 50.0% had a positive reverse-transcription polymerase chain reaction (PCR) result.
We found large differences in the prevalence of SARS-CoV-2 antibodies in staff working in the healthcare sector within a small geographical area of Denmark. Half of all seropositive staff had been tested positive by PCR prior to this survey. This study raises awareness of precautions that should be taken to avoid in-hospital transmission. Regular testing of healthcare workers for SARS-CoV-2 should be considered to identify areas with increased transmission.
本研究旨在对丹麦医护人员中的严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）进行血清流行率调查，以确定高危人群。
丹麦中部地区的 7 家医院、院前服务机构和专科医生诊所的所有医护人员和行政人员均受邀接受一种商用 SARS-CoV-2 总抗体酶联免疫吸附试验（北京万泰生物药业股份有限公司）检测。
共邀请了 25950 名参与者。其中，有 17971 人有 SARS-CoV-2 抗体检测样本。经调整检测的灵敏度和特异性后，总血清流行率为 3.4%（95%置信区间[CI]，2.5%-3.8%）。该地区西部的血清流行率高于东部（11.9%比 1.2%；差异：10.7 个百分点[95%CI，9.5-12.2]）。在高流行地区，急诊科的血清流行率最高（29.7%），而无患者或与患者接触有限的科室的血清流行率最低（2.2%）。在 668 名血清阳性参与者中，433 名（64.8%）此前曾接受过 SARS-CoV-2 RNA 检测，50.0%的人 RT-PCR 结果为阳性。
我们在丹麦一个小地理区域内的医护人员中发现了 SARS-CoV-2 抗体流行率的巨大差异。在此调查之前，所有血清阳性者中有一半的人经 PCR 检测结果为阳性。本研究提高了对在医疗机构内传播应采取的预防措施的认识。应考虑定期对医护人员进行 SARS-CoV-2 检测，以确定传播增加的区域。
